A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia.

n engl j med 362;7 nejm.org february 18, 2010 656 neous regression is never observed, whereas such regression occurs in of 35% of patients with bowenoid papulosis.2 One may wonder whether the complete regression of lesions that was observed in some patients in this clinical trial could be related to a spontaneous regression of multifocal lesions, particularly in very young women (e.g., Patient 11, who was 23 years of age) or in patients with a recent onset (<9 months) of the disease (Patients 11, 27, 29, and 30) or with very small lesions (Patients 11, 16, 27, 29, and 30, who had lesions ranging from 2 cm2 to 8 cm2). Our clinical study involving six women who presented with bowenoid papulosis included a woman who was 23 years of age and who had multifocal lesions (measuring 10 cm2) that underwent spontaneous regression.3